Drug initiatives to improve cognitive function

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 9, 2006, Pages 31-35

  Marder, Stephen R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CENTER; HEALTH PROGRAM; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOCIAL COMPETENCE; SOCIAL PSYCHOLOGY; SOCIAL STATUS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; COGNITION DISORDERS; DRUG INDUSTRY; HUMANS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL ADJUSTMENT; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33748531860     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Lopez-Munoz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 2005;17:113-135
2. Marwaha S, Johnson S. Schizophrenia and employment: a review. Soc Psychiatry Psychiatr Epidemiol 2004;39:337-349
3. Harvey PD, Green MF, Keefe RSE, et al. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004;65:361-372
4. Lieberman JA, Stroup TS, McEvoy JP, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
5. Keefe RS, Silva SG, Perkins DO, et al. Effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-222
6. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-445
7. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 2006;11:11-17
8. Berenson A. Just 20 new products are approved, despite biotechnology's hope. New York Times. January 11, 2006;C:1
9. US Food and Drug Administration. Innovation stagnation: challenge and opportunity on the critical path to new medical products [revised]. March 2004. Available at: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html. Accessed Feb 16, 2006
10. Breier A. Developing drugs for cognitive impairment in schizophrenia. Schizophr Bull 2005;31:816-822
11. Geyer MA, Tamminga CA. Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacol (Berl) 2004;174:1-2
12. Green MF, Nuechterlein K. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 2004;72:1-3
13. Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS). MATRICS - Psychometric Study for the Consensus Battery for Clinical Trials in Schizophrenia. May 22, 2005. Available at: http://www.matrics.ucla. edu/matrics-psychometrics.shtml. Accessed Feb 21, 2006
14. MATRICS-Measurement and Treatment Research to Improve Cognition in Schizophrenia. March 2, 2006. Available at: http://www.matrics.ucla.edu/. Accessed April 5, 2006
15. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004;72:41-51
16. Fenton WS, McGlashan TH, Victor BJ, et al. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 1997;154:199-204
17. Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004;72:29-39
18. Wolwer W, Frommann N, Halfmann S, et al. Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program. Schizophr Res 2005;80:295-303
19. Blanchard JJ, Horan WP, Collins LM. Examining the latent structure of negative symptoms: is there a distinct subtype of negative symptom schizophrenia? Schizophr Res 2005;77:151-165
20. Horan WP, Kring AM, Blanchard JJ. Anhedonia in schizophrenia: a review of assessment strategies. Schizophr Bull 2006;32:259-273
21. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301-307
22. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006;67(suppl 9):3-8
23. Patterson TL, Goldman S, McKibbin CL, et al. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 2001;27:235-245
24. Bellack AS, Sayers M, Mueser KT, et al. Evaluation of social problem solving in schizophrenia. J Abnorm Psychology 1994;103:371-378
25. Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS). MATRICS Meetings. May 22,2005. Available at: http://www.matrics.ucla. edu/matrics-meetings.shtml. Accessed Feb 22, 2006
26. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006;67(suppl 9):9-13
27. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:5-19
28. Bell M, Bryson G, Wexler BE. Cognitive remediation of working memory deficits: durability of training effects in severely impaired and less severely impaired schizophrenia. Acta Psychiatr Scand 2003;108:101-109
29. Silverstein SM, Hatashita-Wong M, Solak BA, et al. Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients. Psychol Med 2005;35:829-837